These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9213079)

  • 1. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment.
    Sundblad C; Wikander I; Andersch B; Eriksson E
    Eur Neuropsychopharmacol; 1997 Aug; 7(3):201-6. PubMed ID: 9213079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols.
    Wu KY; Liu CY; Hsiao MC
    Psychiatry Clin Neurosci; 2008 Feb; 62(1):109-14. PubMed ID: 18289149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxetine as a treatment for premenstrual dysphoric disorder.
    Yonkers KA; Gullion C; Williams A; Novak K; Rush AJ
    J Clin Psychopharmacol; 1996 Feb; 16(1):3-8. PubMed ID: 8834412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome.
    Eriksson E; Hedberg MA; Andersch B; Sundblad C
    Neuropsychopharmacology; 1995 Apr; 12(2):167-76. PubMed ID: 7779245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashes.
    Yonkers KA
    Psychopharmacol Bull; 2003; 37 Suppl 1():135-47. PubMed ID: 14566208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women.
    Steiner M; Ravindran AV; LeMelledo JM; Carter D; Huang JO; Anonychuk AM; Simpson SD
    J Clin Psychiatry; 2008 Jun; 69(6):991-8. PubMed ID: 18517289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
    Miner C; Brown E; McCray S; Gonzales J; Wohlreich M
    Clin Ther; 2002 Mar; 24(3):417-33. PubMed ID: 11952025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder.
    Landén M; Nissbrandt H; Allgulander C; Sörvik K; Ysander C; Eriksson E
    Neuropsychopharmacology; 2007 Jan; 32(1):153-61. PubMed ID: 17035933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptom-onset treatment for women with premenstrual dysphoric disorder.
    Yonkers KA; Holthausen GA; Poschman K; Howell HB
    J Clin Psychopharmacol; 2006 Apr; 26(2):198-202. PubMed ID: 16633152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant-related hypomania in a patient with premenstrual dysphoric disorder.
    Hsiao MC; Liu CY
    J Clin Psychopharmacol; 2002 Oct; 22(5):534-5. PubMed ID: 12352284
    [No Abstract]   [Full Text] [Related]  

  • 11. Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability.
    Landén M; Erlandsson H; Bengtsson F; Andersch B; Eriksson E
    Neuropsychopharmacology; 2009 Feb; 34(3):585-92. PubMed ID: 18596686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial.
    Sundblad C; Hedberg MA; Eriksson E
    Neuropsychopharmacology; 1993 Sep; 9(2):133-45. PubMed ID: 8216696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial.
    Cohen LS; Soares CN; Yonkers KA; Bellew KM; Bridges IM; Steiner M
    Psychosom Med; 2004; 66(5):707-13. PubMed ID: 15385695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent, luteal phase nefazodone treatment of premenstrual dysphoric disorder.
    Kodesh A; Katz S; Lerner AG; Finkel B; Sigal M
    J Psychopharmacol; 2001 Mar; 15(1):58-60. PubMed ID: 11277610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine controlled release.
    Bang LM; Keating GM
    CNS Drugs; 2004; 18(6):355-64; discussion 365-6. PubMed ID: 15089103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series.
    Ravindran LN; Woods SA; Steiner M; Ravindran AV
    Arch Womens Ment Health; 2007; 10(3):125-7. PubMed ID: 17431739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder.
    Steiner M; Hirschberg AL; Bergeron R; Holland F; Gee MD; Van Erp E
    Am J Obstet Gynecol; 2005 Aug; 193(2):352-60. PubMed ID: 16098854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?
    Wikander I; Sundblad C; Andersch B; Dagnell I; Zylberstein D; Bengtsson F; Eriksson E
    J Clin Psychopharmacol; 1998 Oct; 18(5):390-8. PubMed ID: 9790157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder.
    Cohen LS; Soares CN; Lyster A; Cassano P; Brandes M; Leblanc GA
    J Clin Psychopharmacol; 2004 Oct; 24(5):540-3. PubMed ID: 15349012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria.
    Steinberg S; Annable L; Young SN; Liyanage N
    Biol Psychiatry; 1999 Feb; 45(3):313-20. PubMed ID: 10023508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.